Press
Dompé farmaceutici S.p.A and the Chinese Academy of Sciences collaborate on in-depth studies of over 50 molecules active against Sars-Cov-2
June 9, 2020
Dompé to Present Phase II Clinical Data for Ladarixin in New-Onset Type 1 Diabetes (T1D) at the American Diabetes Association’s Scientific Sessions
June 8, 2020
AIFA Announces Italian Authorization of Phase 2/3 Clinical Trial of Dompé's Reparixin for the Treatment of Severe Patients with COVID-19 Pneumonia
May 12, 2020
Exscalate4CoV supercomputing platform wins 3 million euro EU funding to hunt for new drugs against Coronavirus pandemic
March 6, 2020
Exscalate4CoV: EU’s supercomputing and life science champions gear-up to fight Coronavirus pandemic
February 17, 2020
The Galien Foundation Debuts 2019 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories
July 15, 2019
EXSCALATE, EPIDEMICS: Exscalate is the world's most powerful supercomputing platform
April 9, 2019
Dompé receives Industry Innovation Award from the National Organization for Rare Disorders for the Development of Oxervate™ eye drops (cenegermin-bkbj), for neurotrophic keratitis
March 12, 2019
Italian researchers abroad and a startup from Rome win the first Call for Ideas by Dompé. The selected projects concern ophthalmology and the wellness area.
February 20, 2019
Dompé receives FDA approval cenegermin eye drops, first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis
August 22, 2018